Fluoroestradiol F-18
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Fluoroestradiol F-18: From ER-Positive Lesion PET Imaging to Amenorrhea
One-Sentence Summary
Fluoroestradiol F-18 is a radiolabeled estradiol analog, marketed in the US as a PET diagnostic agent for estrogen receptor (ER)-positive lesions. The TxGNN model predicts it may be relevant to amenorrhea, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | PET imaging of ER-positive lesions (diagnostic use; the license record has no indication text) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Based on known information, fluoroestradiol F-18 is an estradiol analog that binds estrogen receptors. It is used as a diagnostic tracer, not as a treatment.
Amenorrhea involves estrogen signaling in the hypothalamic-pituitary-ovarian axis. The model’s high score (0.994) most likely reflects shared ER-related neighbors in the knowledge graph. This is a graph association, not evidence of a therapeutic effect.
There is an important caveat. The drug is given at tracer (microdose) levels to produce an image, not a pharmacological effect. A plausible use in this setting would therefore be diagnostic, for example imaging ER expression in uterine or pituitary tissue. A therapeutic use is not plausible. Neither use is supported by any trial or publication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA212155 | CERIANNA (GE Healthcare Inc.) | Injection | Not listed in the record |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone (L5), with no trials or literature. The drug is a microdose diagnostic tracer, so a therapeutic role in amenorrhea is not credible. Any diagnostic role is untested.
To proceed, the following is needed:
- Package insert warnings and contraindications, which are currently missing and block safety screening
- Mechanism of action data from DrugBank
- A decision on whether the goal is diagnostic imaging or therapy
- Literature and trial searches for ER imaging in amenorrhea and related endocrine conditions
- A route and dosing compatibility assessment for the proposed use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.